Work

Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system

Year: 2025

Type: article

Source: Expert Opinion on Drug Safety

DOI: 10.1080/14740338.2025.2464071

Authors: Jin-Feng Liu, Ying-Tao Bai, Yan-En Leng, En Chang, Yu-Xun Wei, Wei Wei

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407191024

FWCI: 2.736

Cites: 55

Cited by: 2

Related to: 10